Biogen backs FY24 adjusted EPS view of $15.00-$16.00, consensus $15.46

Biogen is reaffirming full year 2024 financial guidance for non-GAAP EPS of $15.00 to $16.00, representing EPS growth of approximately 5% versus 2023 at the mid-point, and continue to expect total revenue to decline by a low- to mid-single digit percentage vs. 2023 and expects core pharmaceutical revenue to be flat vs. 2023. Continues to expect operating income to grow low-double digit percentage vs. 2023 with expected mid-single digit percentage point operating margin improvement.